Biopsy Devices Market Size & Growth Forecast 2026–2035, By Segments (Product), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Biopsy Devices Market size was worth USD 2.55 Billion in 2025 and is expected to grow at a 7.3% CAGR between 2026 and 2035, reaching USD 5.16 Billion by 2035. The industry revenue for 2026 is estimated at USD 2.71 billion.

• Base Year Value (2025): USD 2.55 Billion
• CAGR (2026-2035): 7.3%
• Forecast Year Value (2035): USD 5.16 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Biopsy Devices Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America holds 45.69% share due to high procedural volumes, strong cancer screening programs, established image-guided biopsy pathways, and advanced hospital infrastructure.
  • Asia Pacific is expanding at 8.25% CAGR as diagnostic utilization rises, minimally invasive procedures expand, and healthcare systems increase access to image-supported biopsy techniques.

• Segment Momentum:

  • Needle-based Biopsy Guns held a 45.69% market share in 2025 due to their reliable specimen collection, operator control, clinical familiarity, and compatibility with routine biopsy workflows across healthcare settings.
  • Biopsy Needles are the fastest-growing segment because they support procedure-specific sampling across different tissues and anatomical sites, aligning with growing demand for more targeted and customized biopsy procedures.

• Market Expansion Drivers:

  • Rising global cancer incidence increasing demand for accurate tissue diagnostic procedures.
  • Growing preference for minimally invasive biopsies accelerating innovation in precision biopsy technologies.
  • Expanding healthcare infrastructure in emerging economies improving access to cancer diagnostics.

• Leading Market Participants:

  Major companies in the biopsy devices market include Hologic, Inc. (United States), Danaher Corporation (United States), Cardinal Health, Inc. (United States), Cook Medical LLC (United States), CONMED Corporation (United States), Devicor Medical Products, Inc. (United States), Becton, Dickinson and Company (United States), Argon Medical Devices, Inc. (United States), INRAD, Inc. (United States), Fujifilm Holdings Corporation (Japan).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 2.55 Billion
  • Projected Market Size: USD 5.16 Billion by 2035
  • Growth Forecasts: 7.3% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Needle-based Biopsy Guns (Product)
  • Emerging Opportunity Segment: Biopsy Needles (Product)

Market Growth Drivers and Industry Trends

Rising global cancer incidence increasing demand for accurate tissue diagnostic procedures

As cancer case volumes rise, clinicians are under greater pressure to confirm malignancy earlier and characterize tumors more precisely before treatment decisions are made, which is increasing demand for the biopsy devices market. Tissue sampling remains central to distinguishing benign from malignant lesions, defining histology, and supporting biomarker-based treatment planning, so hospitals and diagnostic centers respond by increasing procedure capacity and standardizing device selection around reliability, sample quality, and procedural efficiency. This raises utilization of core needle, vacuum-assisted, and image-guided biopsy systems, while procurement increasingly favors devices that reduce repeat sampling and support faster diagnostic workflows in the biopsy devices market.

Growing preference for minimally invasive biopsies accelerating innovation in precision biopsy technologies

Patient and provider preference is shifting toward procedures that reduce trauma, shorten recovery time, and lower the need for surgical intervention, creating strong momentum for the biopsy devices market. In practice, this is pushing manufacturers to improve needle guidance, targeting accuracy, sample retrieval consistency, and compatibility with ultrasound, MRI, and stereotactic imaging, since minimally invasive procedures depend on precision rather than open access. The result is stronger adoption of advanced handheld and image-guided systems in outpatient and ambulatory settings, while product development in the biopsy devices market increasingly centers on ease of use, reduced procedural complications, and more dependable tissue acquisition from hard-to-reach lesions.

Expanding healthcare infrastructure in emerging economies improving access to cancer diagnostics

Investment in hospitals, diagnostic laboratories, imaging facilities, and specialty oncology services is making cancer evaluation more available to larger patient populations, encouraging market growth for the biopsy devices market. As emerging healthcare systems build referral networks and add radiology and pathology capabilities, suspicious lesions are more likely to progress from initial detection to confirmatory tissue diagnosis, which directly increases procedure volumes and device demand. This practical shift also changes purchasing behavior in the biopsy devices market, with providers seeking scalable biopsy platforms that fit a wider range of care settings, from urban hospitals to newly equipped regional centers.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising global cancer incidence increasing demand for accurate tissue diagnostic procedures	1.90%	High	North America, Asia Pacific	High	Near Term
Growing preference for minimally invasive biopsies accelerating innovation in precision biopsy technologies	1.70%	Moderate	North America, Europe	High	Mid Term
Expanding healthcare infrastructure in emerging economies improving access to cancer diagnostics	1.40%	Moderate	Asia Pacific, Latin America	Emerging	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held a 45.69% share of the biopsy devices market in 2025, supported by broad procedural volumes, established diagnostic pathways, and strong access to image-guided interventions across hospital and specialty care settings. The region’s leadership is strengthened by routine cancer screening and early detection practices that keep demand steady for core needle, vacuum-assisted, and minimally invasive biopsy procedures. Market activity is further supported by provider familiarity with advanced biopsy platforms and the availability of healthcare infrastructure that allows faster integration of upgraded devices into daily clinical workflows.

Asia Pacific is projected to expand at an 8.25% CAGR over the forecast period in the biopsy devices market, driven by rising diagnostic utilization and wider adoption of minimally invasive tissue sampling across developing and mature healthcare systems in the region. Growth is accelerating as more patients enter formal diagnostic pathways, while hospitals and diagnostic centers continue adding procedural capacity for earlier and more accurate lesion assessment. The region is also seeing stronger uptake of modern biopsy techniques as healthcare access improves and clinical practice increasingly shifts toward image-supported, precision-focused diagnosis.

Key Country Insights

United States

Precision Diagnostics Adoption

The U.S. biopsy devices market is driven by growing use of image-guided and minimally invasive diagnostic procedures across oncology and specialty care. Healthcare providers continue investing in advanced biopsy technologies that improve diagnostic accuracy while supporting efficient clinical workflows.

Japan

Minimally Invasive Care

Japan prioritizes minimally invasive biopsy procedures that align with patient-centered healthcare and early disease detection initiatives. Medical institutions increasingly adopt precision biopsy devices that enhance procedural consistency and support improved diagnostic outcomes.

South Korea

Technology-Enabled Diagnostics

South Korea continues expanding the use of advanced biopsy devices through investments in digital healthcare infrastructure and modern diagnostic capabilities. Hospitals increasingly integrate image-guided technologies that improve procedural efficiency and support accurate tissue sampling.

Germany

Clinical Imaging Integration

Germany emphasizes the integration of biopsy devices with advanced imaging systems to strengthen diagnostic precision in hospitals and specialized care centers. Manufacturers focus on reliable instrument performance and workflow efficiency to support evolving clinical practice requirements.

France

Oncology Care Support

France focuses on strengthening biopsy device adoption within oncology and specialized diagnostic services where accurate tissue collection remains essential. Healthcare providers increasingly standardize advanced biopsy procedures to improve patient management and laboratory efficiency.

Italy

Hospital Procedure Optimization

Italy supports broader adoption of biopsy devices through hospital modernization and improved access to minimally invasive diagnostic procedures. Clinical teams continue selecting technologies that streamline workflows while enhancing diagnostic confidence across multiple medical specialties.

Segment Leadership and Growth Trends

  Product Segment Analysis: Needle-based Biopsy Guns (Largest Segment) vs Biopsy Needles (Fastest-Growing Segment)

Needle-based Biopsy Guns held a 45.69% share of the biopsy devices market in 2025, reflecting their established role in routine tissue sampling procedures where procedural consistency and operator control are critical. Their leadership is reinforced through broad clinical familiarity, reliable specimen collection performance, and compatibility with standard biopsy workflows across hospitals and diagnostic centers. In the biopsy devices market, this segment continues to benefit from its practical value in enabling efficient, repeatable sampling during image-guided and manual procedures, which helps sustain its leading share.

Biopsy Needles are emerging as the fastest-growing product segment in the biopsy devices market as providers place greater emphasis on procedure-specific sampling approaches and precision across a widening range of biopsy applications. Growth is being reinforced through the need for needle options tailored to different tissue types, anatomical sites, and diagnostic requirements, giving this segment stronger momentum relative to more fixed device formats. As biopsy practices become more targeted and clinically customized, demand for biopsy needles is rising because they align closely with evolving procedural requirements and expanding diagnostic use cases.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Product	Needle-based Biopsy Guns, Biopsy Guidance Systems, Biopsy Needles, Biopsy Forceps, Others	Needle-based Biopsy Guns	Biopsy Needles

Competitive Landscape and Market Positioning

Top players in the biopsy devices market:

1. Hologic Inc. (United States)

2. Danaher Corporation (United States)

3. Cardinal Health Inc. (United States)

4. Cook Medical LLC (United States)

5. CONMED Corporation (United States)

6. Devicor Medical Products Inc. (United States)

7. Becton Dickinson and Company (United States)

8. Argon Medical Devices Inc. (United States)

9. INRAD Inc. (United States)

10. Fujifilm Holdings Corporation (Japan)

The biopsy devices market is advancing through improved diagnostic precision and minimally invasive technologies. Innovation is enhancing sampling accuracy and procedural efficiency. Continuous development is supporting better clinical outcomes. Growing demand for early diagnosis is strengthening device adoption.

Industry Development/News

Company Name	Date	Key Development
Halma plc	Nov-24	Halma plc completed a £42 million acquisition of Lamidey Noury Medical, a French manufacturer of advanced electrosurgical devices. This strategic move expands Halma's healthcare portfolio into minimally invasive surgical and diagnostic energy technologies, providing adjacent capabilities that complement its existing presence in the biopsy and medical device markets.
Mammotome	Nov-24	Mammotome, a subsidiary of Devicor, launched the AutoCore biopsy system, designed for breast tissue examinations. The device introduces automated spring-loaded capabilities that improve upon traditional core needle instruments, enhancing procedural efficiency for healthcare providers and reducing the time required to obtain high-quality tissue samples during biopsies.
Single Pass	Apr-24	Single Pass received FDA clearance for its Kronos biopsy closure device, a Class II medical device. The system utilizes electrocautery to facilitate tract closure and hemostasis following percutaneous solid organ biopsies, addressing a critical need to minimize post-procedural bleeding complications in high-risk biopsy applications such as kidney and lung sampling.
Mammotome	Aug-23	Mammotome launched the HydroMARK Plus Breast Biopsy Site Marker, a diagnostic accessory designed to improve the accuracy of tissue marking. By mitigating the risk of marker displacement, this technology enhances post-biopsy visualization and patient monitoring, representing a meaningful innovation in clinical biopsy workflows and diagnostic follow-up.
Argon Medical Devices	May-23	Argon Medical Devices introduced the SuperCore Advantage semi-automatic biopsy instrument for soft tissue applications. The device features increased spring strength and an integrated coaxial adapter to maximize sample yield, effectively reducing the number of needle passes required during diagnostic procedures and improving clinical efficiency for a variety of tissue sampling tasks.